Emicizumab Prophylaxis in Persons with Hemophilia A, Aged ≥50 Years, with Comorbidities - Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY)

Background: Emicizumab is indicated for prophylaxis in persons with hemophilia A (PwHA) of all ages, with/without factor (F)VIII inhibitors (exact label may vary by country). For older persons receiving emicizumab, however, their care may be complicated by comorbidities. Prevalence and early onset of cardiovascular (CV) risk factors, including hypertension, are common among PwHA (Humphries, et al. Adv Med Sci 2018; Sood, et al. Blood Adv 2018). Human immunodeficiency virus (HIV), which is likely to be more common in older PwHA, is associated with increased risk of heart disease (Shah, et al. Circulation 2018), and co-infection of HIV with hepatitis C virus (HCV) increases the risk of end-stage liver disease and worsens HCV progression (Papadopoulos, et al. Ann Gastroenterol 2018). Data regarding emicizumab in older PwHA with comorbidities (CV risk factors or concomitant HIV and/or HCV infection) are limited. This post hoc analysis of PwHA in four Phase III studies evaluated efficacy and safety of emicizumab in PwHA aged ≥50 years with CV risk factors or HIV and/or HCV infection.